Proteomics study the potential targets for Rifampicin-resistant spinal tuberculosis

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Rifampicin-resistant tuberculosis (TB) presents a global health challenge, especially spinal TB (DSTB).
• Suboptimal treatment outcomes and lack of guidelines for DSTB hinder effective management.
• There is an urgent need for novel drugs to combat Rifampicin-resistant DSTB.

Purpose of the Study:

• To identify potential therapeutic targets for DSTB using proteomic and pharmaco-transcriptomic analyses.
• To investigate molecular mechanisms underlying Rifampicin-resistant spinal tuberculosis.
• To explore drug compounds that can modulate key targets in DSTB.

Main Methods:

• Mass spectrometry-based proteomics to identify differentially expressed proteins (DEPs).
• Network pharmacology for key target identification and pathway analysis (GO, KEGG).
• Pharmaco-transcriptomic analysis to identify potential drug compounds.

Main Results:

• Identified 373 DEPs (137 upregulated, 236 downregulated) in DSTB.
• Network pharmacology pinpointed five key targets: HLAA, HLA-C, HLA-DRB1, MMP9, and PLCL1.
• Fifty-eight drug compounds were found to regulate these key targets, implicated in 'Antigen processing and presentation' and 'Phagosome' pathways.

Conclusions:

• Protein alterations are confirmed in Rifampicin-resistant DSTB patients.
• The study provides novel molecular insights into DSTB pathogenesis.
• Findings support the development of targeted therapies for Rifampicin-resistant spinal tuberculosis.